Novo’s Oral Semaglutide Delivers Similar Weight Loss To Wegovy In Phase III
Executive Summary
A 50mg dose of oral semaglutide showed similar weight loss to the weekly injectable version that Novo already markets as Wegovy.
You may also be interested in...
Prospective Peptide Manufacturer Passes US Inspection In China
Chinese CDMO Aurisco has welcomed a key step on its journey to advance from complex generic APIs and small molecule to peptides and oligonucleotides.
Pfizer Sees Once Daily Danuglipron In The “Reasonable Future”
The obesity market offers big revenue potential but Pfizer’s oral GLP-1 candidate is currently dosed twice daily.
William Pao On Pfizer’s ‘Aspirational’ Drug Development Goal, Seagen And More
Chief development officer William Pao oversees Pfizer’s clinical pipeline. He joined the company from Roche following a career in academia, and after his first year at Pfizer talked to Scrip about the transition to late-stage drug development.